Korea Institute of Science and Technology

Industry-university Cooperation Foundation Hanyang University

Korea Research Institute of Chemical Technology

Korea Research Institute of Bioscience and Biotechnology

Hanmi Pharm. Co., Ltd.

Hanmi Science Co., Ltd.

Jung Mi Hah

Hwan Geun Choi

Tae Bo Sim

Young Jin Ham

Hwan Mook Kim

Kyung Ho Yoo

Chang Hyun Oh

Hwan Oh Kim

Jung Beom Son

Dong Sik Park

Eun Jin Jun

Jung Hun Lee

Young Gil Ahn

Sung Yun Cho

Maeng Sup Kim

Dong Cho Han

Jae Du Ha

Seung Hyun Jung

Byoung Mog Kwon

Young Hee Jung

Mi Kyoung Lee

So Ha Lee

Tae Hun Song

Dong-sik Park

Jung-Hun Lee

Da Seul Im

Eun Ju Jeon

Song I Yang

Wha Il Choi

Myoung Sil Ko

In Ho Yang

The present invention relates to a novel benzimidazole derivative having fms-like tyrosine kinase 3 (FLT3) inhibitory activity, and a use thereof. A novel benzimidazole derivative or a pharmaceutically acceptable salt thereof, according to the present invention, exhibits excellent inhibitory activity against FLT3, and thus targeted treatment through more fundamental approaches is expected in the prevention or treatment of acute myeloid leukemia (AML).

Imidazole derivative expressing FLT3 inhibitory activity, and use thereof

The present invention relates to a novel benzimidazole derivative having JNK (C-Jun N-terminal kinase) inhibitory activity and use thereof. The novel benzimidazole derivative or a pharmaceutically acceptable salt thereof according to the present invention exhibits excellent inhibitory activity against c-Jun N-terminal kinase 3(JNK 3), and thus it is expected that target therapy can be attained through a more fundamental approach in the prevention or treatment of degenerative brain-nerve system disease.

Benzimidazole derivative having JNK inhibitory activity and use thereof

The present invention relates to a novel bicyclic heteroaryl derivative, a pharmaceutically acceptable salt thereof, a hydrate thereof, and a solvate thereof having an improved inhibitory activity for protein kinases, and a pharmaceutical composition for preventing or treating an abnormal cell growth disorder comprising same as an active ingredient.

Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase

A substituted thieno pyrimidine compound of Formula 1, pharmaceutically acceptable salts and a pharmaceutical composition thereof is provided.  The compound of Formula 1 exhibits superior inhibition activity against various protein kinases involved in growth factor signal transduction. The compound of Formula 1 and its compositions are useful for the prevention and treatment of diseases caused by abnormal cell growth including cancer.

2,4,7-substituted thieno[3,2-d]pyrimidine compounds as protein kinase inhibitors

Disclosed are a 1,6-substituted indole compound having a protein kinase inhibition activity, a pharmaceutically acceptable salt, and a pharmaceutical composition for prevention and treatment of cancers caused by abnormal cell growth comprising the compound as an effective ingredient. Since the novel indole compound exhibits superior inhibition activity against various protein kinases involved in growth factor signal transduction, it is useful as an agent for preventing or treating cancers caused by abnormal cell growth.

1,6-disubstituted indole compounds as protein kinase inhibitors

Disclosed are novel indazole derivatives represented by the following Chemical Formula 1 or pharmaceutically acceptable salts, hydrates or solvates thereof, and pharmaceutical compositions for the prevention or treatment of proliferative diseases, containing the same as an active ingredient. Having potent inhibitory effect against protein kinase, such as b-raf, KDR, Fms, Tie2, SAPK2a and Ret, inducing diseases caused by abnormal cell proliferation, the novel indazole derivatives can be used for the prevention or treatment of diseases caused by abnormal cell proliferation.

Indazole derivatives or pharmaceutically acceptable salts thereof as protein kinase inhibitors for proliferative diseases treatment, and a pharmaceutical composition containing the same as an active ingredient

Disclosed are a 2,7-substituted thieno[3,2-d]pyrimidine compound having a protein kinase inhibition activity, a pharmaceutically acceptable salt, and a pharmaceutical composition for prevention and treatment of diseases caused by abnormal cell growth comprising the compound as an effective ingredient. Since the novel 2,7-substituted thieno[3,2-d]pyrimidine compound exhibits superior inhibition activity against various protein kinases involved in growth factor signal transduction, it is useful as an agent for preventing or treating diseases caused by abnormal cell growth.

2,7-substituted thieno[3,2-d] pyrimidine compounds as protein kinase inhibitors

Disclosed are a 1,3,6-substituted indole compound having inhibitory activity for protein kinases, a pharmaceutically acceptable thereof, and a pharmaceutical composition for prevention and treatment of diseases caused by abnormal cell growth including the compound as an active ingredient. Since the novel indole compound exhibits superior inhibitory activity for various protein kinases involved in growth factor signal transduction, it is useful as an agent for preventing or treating cancers caused by abnormal cell growth.

1,3,6-substituted indole derivatives having inhibitory activity for protein kinase

Growing community of inventors

Seoul, South Korea

Jung Mi Hah